Chemical Properties:
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureCommercial Supply Related Intermediates: CAS: 242478-38-2 (R)-(-)-3-Quinuclidinol CAS: 25333-42-0 (S)-(+)-3-Quinuclidinol CAS: 34583-34-1 3-Quinuclidinone Hydrochloride CAS: 1193-65-3 1-Phenyl-1,2,3,4-Tetrahydro-Isoquinoline CAS: 22990-19-8 (S)-1-Phenyl-1,2,3,4-Tetrahydroisoquinoline CAS: 118864-75-8| Item | Specifications |
| Appearance | White or Almost White Crystalline Powder |
| Identification | By IR; By HPLC |
| Solubility | Freely Soluble in Acetic Acid, Water, Methanol |
| Melting Point | 144.0~150.0℃ |
| Specific Optical Rotation | +88.0º~+94.0º |
| Loss on Drying | ≤0.50% |
| Residue on Ignition | ≤0.10% |
| 3-Quinuclidinol | ≤0.20% |
| Succinate Content | 23.5~25.5% |
| Optical Isomer | |
| Diastereoisomer RS | ≤0.15% |
| Diastereoisomer SS | ≤0.15% |
| Diastereoisomer RR | ≤0.20% |
| Residual Solvents | |
| Acetone | ≤5000ppm |
| Dichloromethane | ≤600ppm |
| Toulene | ≤890ppm |
| Diisopropyl Ether | ≤500ppm |
| Dimethyl Formamide | ≤880ppm |
| Related Substances | |
| Any Single Impurity | ≤0.10% |
| Total Impurities | ≤0.50% |
| Heavy Metals | ≤20ppm |
| Purity / Analysis Method | ≥99.5% (HPLC on dried basis) |
| Test Standard | Enterprise Standard |
| Usage | API; Overactive Bladder |
Description:
Specifications:
Package & Storage:
| Synonyms | Vesicare; 1-Azabicyclo[2.2.2]octan-8-yl (1S)-1-phenyl-3,4-dihydro-1H-isoquinoline-2-carboxylate butanedioic acid |
| CAS Number | 242478-38-2 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C23H26N2O2·C4H6O4 |
| Molecular Weight | 480.56 |
| Brand | Ruifu Chemical |
Advantages:
FAQ:
Application:
API (CAS: 242478-38-2) is an antimuscarinic medication that is used to treat an overactive bladder causing symptoms of frequency, urgency, or incontinence. It is an M3 muscarinic receptor antagonist that was developed and launched for the treatment of overactive bladder (pollakiuria) in Europe. M3 receptors have been implicated in neurally evoked smooth muscle contractions of the bladder, and M2 receptors have also been suspected of playing a role because of their dominance in the detrusor muscle. It is used for Urological medicine. It is a urinary antispasmodic of the antimuscarinic class.
